Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Recruiting · NCT07486869 · Registry updated 2026-08-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | Skin and Connective Tissue Diseases, amyopathic dermatomyositis, connective tissue disorder, dermatomyositis, interstitial lung disease, lung disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, respiratory system disorder, skin disorder | Recruiting | Phase 2 | 2026-08-25 | NCT07486869 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Swedish Orphan Biovitrum | 21 |
| University of Miami | 277 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Miami Hospital and Clinics | Miami | United States | 20 |